A phase I/II study of SDZ PSC 833 (PSC) in combination with daunorubicin (D) and cytarabine in refractory acute myelogenous leukemia (AML).

被引：0
|
作者：
Liliemark, J
Bjorkholm, M
Uden, AM
Hast, R
Paul, C
Simonsson, B
Tidefelt, U
Juliusson, G
Hedenus, M
Evensen, S
Tangen, JM
Sjo, M
Nesthus, I
Hestdal, K
机构：
[1] KAROLINSKA HOSP,DEPT ONCOL,S-10401 STOCKHOLM,SWEDEN
[2] KAROLINSKA HOSP,DEPT HEMATOL,S-10401 STOCKHOLM,SWEDEN
[3] SODER SJUKHUSET,DEPT HEMATOL,STOCKHOLM,SWEDEN
[4] DANDERYD HOSP,DEPT HEMATOL,STOCKHOLM,SWEDEN
[5] HUDDINGE HOSP,DEPT HEMATOL,STOCKHOLM,SWEDEN
[6] UNIV UPPSALA HOSP,DEPT HEMATOL,UPPSALA,SWEDEN
[7] REG HOSP,DEPT HEMATOL,OREBRO,SWEDEN
[8] LINKOPING UNIV HOSP,DEPT HEMATOL,S-58185 LINKOPING,SWEDEN
[9] SUNDSVALL HOSP,DEPT HEMATOL,SUNDSVALL,SWEDEN
[10] ULLEVAL HOSP,RIKSHOSP,DEPT HEMATOL,OSLO,NORWAY
[11] REG HOSP,DEPT HEMATOL,TROMSO,NORWAY
[12] HAUKELAND HOSP,DEPT HEMATOL,N-5021 BERGEN,NORWAY
[13] SANDOZ,DEPT HEMATOL,OSLO,NORWAY
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：854 / 854
页数：1
相关论文
共 50 条
  • [21] Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995).
    Greenberg, P
    Advani, R
    Tallman, M
    Letendre, L
    Saba, H
    Dugan, K
    Lee, SJ
    Lum, B
    Sikic, BI
    Paietta, E
    Bennett, J
    Rowe, JM
    BLOOD, 1999, 94 (10) : 383A - 383A
  • [22] Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833
    Chico, I
    Kang, MH
    Bergan, R
    Abraham, J
    Bakke, S
    Meadows, B
    Rutt, A
    Robey, R
    Choyke, P
    Merino, M
    Goldspiel, B
    Smith, T
    Steinberg, S
    Figg, WD
    Fojo, T
    Bates, S
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) : 832 - 842
  • [23] A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia
    Bauer, KS
    Karp, JE
    Garimella, TS
    Wu, SL
    Tan, M
    Ross, DD
    LEUKEMIA RESEARCH, 2005, 29 (03) : 263 - 271
  • [24] Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia
    Merlin, JL
    Guerci, AP
    Marchal, S
    Bour, C
    Colosetti, P
    Kataki, A
    Guerci, O
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (02) : 480 - 487
  • [25] Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: A gynecologic oncology group study
    Fracasso, PM
    Brady, MF
    Moore, DH
    Walker, JL
    Rose, PG
    Letvak, L
    Grogan, TM
    McGuire, WP
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (12) : 2975 - 2982
  • [26] A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar)
    Bates, S
    Kang, M
    Meadows, B
    Bakke, S
    Choyke, P
    Merino, M
    Goldspiel, B
    Chico, I
    Smith, T
    Chen, C
    Robey, R
    Bergan, R
    Figg, WD
    Fojo, T
    CANCER, 2001, 92 (06) : 1577 - 1590
  • [27] Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia
    Attar, Eyal C.
    De Angelo, Daniel J.
    Supko, Jeffrey G.
    D'Amato, Ferdinando
    Zahrieh, David
    Sirulnik, Andres
    Wadleigh, Martha
    Ballen, Karen K.
    McAfee, Steve
    Miller, Kenneth B.
    Levine, James
    Galinsky, Ilene
    Trehu, Elizabeth G.
    Schenkein, David
    Neuberg, Donna
    Stone, Richard M.
    Amrein, Philip C.
    CLINICAL CANCER RESEARCH, 2008, 14 (05) : 1446 - 1454
  • [28] Phase I Study of Valspodar (PSC-833) With Mitoxantrone and Etoposide in Refractory and Relapsed Pediatric Acute Leukemia: A Report From the Children's Oncology Group
    O'Brien, Maureen M.
    Lacayo, Norman J.
    Lum, Bert L.
    Kshirsagar, Smita
    Buck, Steven
    Ravindranath, Yaddanapudi
    Bernstein, Mark
    Weinstein, Howard
    Chang, Myron N.
    Arceci, Robert J.
    Sikic, Branimir I.
    Dahl, Gary V.
    PEDIATRIC BLOOD & CANCER, 2010, 54 (05) : 694 - 702
  • [29] Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia (vol 19, pg 1589, 2001)
    Dorr
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) : 2583 - 2583
  • [30] Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Naqvi, Kiran
    Ravandi, Farhad
    Kantarjian, Hagop
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Thomas, Deborah A.
    Koller, Charles Asa
    Konopleva, Marina
    Byrd, Anna
    Kwari, Monica
    Faderl, Stefan
    BLOOD, 2010, 116 (21) : 464 - 465
12345